SCHEMBL3468635

SCHEMBL3468635

CCC(=O)OCOC(=O)N1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.54
MEN1 O00255 2/20 0.54
MAPK1 P28482 2/20 0.54
KMT2A Q03164 2/20 0.54
POLB P06746 1/20 0.54
MAPT P10636 1/20 0.54
CASP1 P29466 1/20 0.54
CASP7 P55210 1/20 0.54
DRD2 P14416 4/20 0.52
LMNA P02545 2/20 0.52
CHRM2 P08172 2/20 0.52
HTR1A P08908 2/20 0.52
ADRA2A P08913 2/20 0.52
CHRM1 P11229 2/20 0.52
ADRA2B P18089 2/20 0.52
ADRA2C P18825 2/20 0.52
CHRM3 P20309 2/20 0.52
DRD1 P21728 2/20 0.52
HTR2A P28223 2/20 0.52
HTR2C P28335 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3468502 0.91 DRD2 (0.53) KDM4EMEN1MAPK1KMT2APOLB
SCHEMBL3468838 0.84 DRD2 (0.58) KDM4EMEN1MAPK1KMT2APOLB
SCHEMBL3229794 0.81 DRD2 (0.55) KDM4EMEN1MAPK1KMT2APOLB
SCHEMBL2369778 0.80 DRD2 (0.62) KDM4EMEN1MAPK1KMT2AMAPT
SCHEMBL5946399 0.80 DRD2 (0.67) KDM4EMEN1MAPK1KMT2APOLB
SCHEMBL2036762 0.80 DRD2 (0.67) KDM4EMEN1MAPK1KMT2APOLB
SCHEMBL2370824 0.80 DRD2 (0.56) KDM4EMEN1MAPK1KMT2APOLB
SCHEMBL3216890 0.79 DRD2 (0.64) KDM4EMEN1MAPK1KMT2ADRD2
SCHEMBL13538994 0.78 KDM4E (0.48) KDM4EMEN1MAPK1KMT2APOLB
SCHEMBL2369873 0.78 DRD2 (0.54) KDM4EMEN1MAPK1KMT2ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016283-A1 COMPOUNDS AND USES THEREOF - 150 ASTRAZENECA AB (SE) 2010-01-21 US disclosed
US-20100016283-A1 COMPOUNDS AND USES THEREOF - 150 ASTRAZENECA AB (SE) 2010-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016283-A1 COMPOUNDS AND USES THEREOF - 150 MAPT, PSEN1, BACE1 KDM4E 2834/4885MEN1 1592/4885MAPK1 3527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.